clinical trial · NCT07189949
A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Jiangsu HengRui Medicine Co., Ltd.·phase1·recruiting·n = 120
Advanced Solid Tumors Harboring RAS Mutations or AmplificationsHRS-2329 Tablet
brief summary
This is an open-label, multi-center phase I clinical study to evaluate the safety, tolerability, and pharmacokinetics of HRS-2329 in participants with advanced solid tumors harboring RAS mutations or amplifications.
started
Oct 16, 2025
primary completion
Dec 1, 2028
completion
Dec 1, 2028
last updated
Mar 6, 2026
official title
A Phase I Study of HRS-2329 Evaluating Safety, Tolerability, and Pharmacokinetics in Subjects With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol